Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Should You Buy Novavax on the Dip?

TheMotleyFool

0 0

Novavax (NASDAQ: NVAX) soared to stardom last year as investors bet on the prospects of its coronavirus vaccine candidate. As a result, the stock surged 2,700% in 2020.

Novavax shares have increased this year, but a lot less -- about 80%. Why? Investors lost patience with the company. Manufacturing and raw materials issues have delayed Novavax's submission for Emergency Use Authorization to the Food and Drug Administration. Now a new issue is arising. This week, investors started worrying about the post-pandemic outlook for vaccine sales. Novavax stock lost 20% in four trading sessions. Should you flee the stock -- or should you buy on the dip?

Image source: Getty Images.

Source Fool.com

Like: 0

NVAX

Share